home

Novartis muscular drug fails in Phase III trials

Trendpharmafile2016-04-25 15:02 Read   114

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint in a Phase IIb/III study, raising doubts over the future of BYM338 (bimagrumab) which was originally designated a “breakthrough” therapy by the US Food and Drug Administration.

FirstWord Lists: The 50 fastest growing pharmaceutical brands in 2015

CommentsFirstWord2016-04-25 14:47 Read   191

The 50 fastest growing pharmaceutical products (calculated by subtracting 2014 sales from 2015 sales) generated combined year-on-year growth of $41 billion in 2015.

Immunotherapy, Global Health & More At Seattle’s Life Sci Disruptors

Meetingxconomy2016-04-25 10:30 Read   83

Our annual life sciences forum in Seattle is coming up on May 2 at the Fred Hutchinson Cancer Research Center, and we’re looking forward to an afternoon of discussions that tap into the city’s biotech and public health expertise.

Pharma and payers agree: It's time for more dialogue on drug pricing

Commentsfiercepharma2016-04-25 10:17 Read   78

When it comes to rising drug costs, payers and pharma rarely see eye-to-eye. But more back-and-forth conversation could go a long way in easing some of the tension, both sides are saying. And a little regulatory overhaul could help make this a possibility.

Industry welcomes India regulator notice on academic trials

Commentsfiercepharma2016-04-25 10:09 Read   86

A notice by the Drug Controller General of India (DCGI) has paved the way for a variety of much needed new clinical research by academics on already approved drugs, the Indian Society for Clinical Research (ISCR) said.

Novartis' Entresto uptake better in EU as U.S. warms slowly to new heart meds

EVENTSfiercepharma2016-04-25 09:56 Read   82

Drugmakers generally expect to make most of their money on new drugs in the U.S., the world’s largest market with the most liberal payment system.

Novartis splits U.S. honcho's job in two as current chief Christi Shaw steps down

EVENTSfiercepharma2016-04-25 09:47 Read   242

Novartis will see a changing of the guard in the U.S. next week. Christi Shaw, who has headed up the Swiss drugmaker’s U.S. operations since April 2014, is stepping down for personal and family reasons, to be replaced by two current Novartis execs.

States' efforts to fight skyrocketing costs pose 'modest risk to pharma': Report

Regulatorfiercepharma2016-04-25 09:42 Read   79

States across the country have been battling it out with Big Pharma over drug pricing, with some introducing bills that take aim at skyrocketing costs.

Expert Offers Advice on Treating Corns, Calluses

Healthdrugs2016-04-25 09:35 Read   73

Corns and calluses form due to friction or pressure on the skin, and there are a number of ways to treat these often unsightly areas, an expert says.

Health Tip: Keep Skin Looking Young

HealthDRUGS2016-04-25 09:32 Read   96

Your skin may be exposed to plenty of things that can make it look older, including the sun, pollution and harsh skin-care products.

U.S. Suicide Rate Up 24 Percent Since 1999: CDC

CommentsDRUGS2016-04-25 09:28 Read   73

Suicide rates in the United States rose 24 percent between 1999 and 2014, with young girls and middle-aged men accounting for the largest increases, federal health officials reported Friday.

Medpace seeking $1B public offering: Reuters

EVENTSfiercebiotech2016-04-25 09:22 Read   83

Cincinnati CRO Medpace is looking to float for more than $1 billion, according to reports from Reuters quoting people “familiar with the matter.”